98 results on '"Gaziano, J Michael"'
Search Results
2. Early Outcomes of SARS-CoV-2 Infection in a Multisite Prospective Cohort of Inpatient Veterans.
- Author
-
Ross, Jennifer M, Sugimoto, Jonathan D, Timmons, Andrew, Adams, Jonathan, Deardoff, Katrina, Korpak, Anna, Liu, Cindy, Moore, Kathryn, Wilson, Deanna, Bedimo, Roger, Chang, Kyong-Mi, Cho, Kelly, Crothers, Kristina, Garshick, Eric, Gaziano, J Michael, Holodniy, Mark, Hunt, Christine M, Isaacs, Stuart N, Le, Elizabeth, and Jones, Barbara E
- Subjects
SARS-CoV-2 ,COVID-19 ,VACCINATION status - Abstract
Background Over 870 000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have occurred among Veterans Health Administration users, and 24 000 have resulted in death. We examined early outcomes of SARS-CoV-2 infection in hospitalized veterans. Methods In an ongoing, prospective cohort study, we enrolled veterans age ≥18 tested for SARS-CoV-2 and hospitalized at 15 Department of Veterans Affairs medical centers between February 2021 and June 2022. We estimated adjusted odds ratios (aORs), adjusted incidence rate ratios (aIRRs), and adjusted hazard ratios (aHRs) for maximum illness severity within 30 days of study entry (defined using the 4-category VA Severity Index for coronavirus disease 2019 [COVID-19]), as well as length of hospitalization and rehospitalization within 60 days, in relationship with demographic characteristics, Charlson comorbidity index (CCI), COVID-19 vaccination, and calendar period of enrollment. Results The 542 participants included 329 (61%) who completed a primary vaccine series (with or without booster; "vaccinated"), 292 (54%) enrolled as SARS-CoV-2-positive, and 503 (93%) men, with a mean age of 64.4 years. High CCI scores (≥5) occurred in 61 (44%) vaccinated and 29 (19%) unvaccinated SARS-CoV-2-positive participants. Severe illness or death occurred in 29 (21%; 6% died) vaccinated and 31 (20%; 2% died) unvaccinated SARS-CoV-2-positive participants. SARS-CoV-2-positive inpatients per unit increase in CCI had greater multivariable-adjusted odds of severe illness (aOR, 1.21; 95% CI, 1.01–1.45), more hospitalization days (aIRR, 1.06; 95% CI, 1.03–1.10), and rehospitalization (aHR, 1.07; 95% CI, 1.01–1.12). Conclusions In a cohort of hospitalized US veterans with SARS-CoV-2 infection, those with a higher CCI had more severe COVID-19 illness, more hospital days, and rehospitalization, after adjusting for vaccination status, age, sex, and calendar period. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Framework of the Centralized Interactive Phenomics Resource (CIPHER) standard for electronic health data-based phenomics knowledgebase.
- Author
-
Honerlaw, Jacqueline, Ho, Yuk-Lam, Fontin, Francesca, Gosian, Jeffrey, Maripuri, Monika, Murray, Michael, Sangar, Rahul, Galloway, Ashley, Zimolzak, Andrew J, Whitbourne, Stacey B, Casas, Juan P, Ramoni, Rachel B, Gagnon, David R, Cai, Tianxi, Liao, Katherine P, Gaziano, J Michael, Muralidhar, Sumitra, and Cho, Kelly
- Abstract
The development of phenotypes using electronic health records is a resource-intensive process. Therefore, the cataloging of phenotype algorithm metadata for reuse is critical to accelerate clinical research. The Department of Veterans Affairs (VA) has developed a standard for phenotype metadata collection which is currently used in the VA phenomics knowledgebase library, CIPHER (Centralized Interactive Phenomics Resource), to capture over 5000 phenotypes. The CIPHER standard improves upon existing phenotype library metadata collection by capturing the context of algorithm development, phenotyping method used, and approach to validation. While the standard was iteratively developed with VA phenomics experts, it is applicable to the capture of phenotypes across healthcare systems. We describe the framework of the CIPHER standard for phenotype metadata collection, the rationale for its development, and its current application to the largest healthcare system in the United States. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Multimodal representation learning for predicting molecule–disease relations.
- Author
-
Wen, Jun, Zhang, Xiang, Rush, Everett, Panickan, Vidul A, Li, Xingyu, Cai, Tianrun, Zhou, Doudou, Ho, Yuk-Lam, Costa, Lauren, Begoli, Edmon, Hong, Chuan, Gaziano, J Michael, Cho, Kelly, Lu, Junwei, Liao, Katherine P, Zitnik, Marinka, and Cai, Tianxi
- Subjects
PROTEIN-protein interactions ,ELECTRONIC health records ,DIGITAL learning ,CHEMICAL properties ,DRUG development - Abstract
Motivation Predicting molecule–disease indications and side effects is important for drug development and pharmacovigilance. Comprehensively mining molecule–molecule, molecule–disease and disease–disease semantic dependencies can potentially improve prediction performance. Methods We introduce a Multi-Modal REpresentation Mapping Approach to Predicting molecular-disease relations (M2REMAP) by incorporating clinical semantics learned from electronic health records (EHR) of 12.6 million patients. Specifically, M2REMAP first learns a multimodal molecule representation that synthesizes chemical property and clinical semantic information by mapping molecule chemicals via a deep neural network onto the clinical semantic embedding space shared by drugs, diseases and other common clinical concepts. To infer molecule–disease relations, M2REMAP combines multimodal molecule representation and disease semantic embedding to jointly infer indications and side effects. Results We extensively evaluate M2REMAP on molecule indications, side effects and interactions. Results show that incorporating EHR embeddings improves performance significantly, for example, attaining an improvement over the baseline models by 23.6% in PRC-AUC on indications and 23.9% on side effects. Further, M2REMAP overcomes the limitation of existing methods and effectively predicts drugs for novel diseases and emerging pathogens. Availability and implementation The code is available at https://github.com/celehs/M2REMAP , and prediction results are provided at https://shiny.parse-health.org/drugs-diseases-dev/. Supplementary information Supplementary data are available at Bioinformatics online. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.
- Author
-
Pagadala, Meghana S, Lynch, Julie, Karunamuni, Roshan, Alba, Patrick R, Lee, Kyung Min, Agiri, Fatai Y, Anglin, Tori, Carter, Hannah, Gaziano, J Michael, Jasuja, Guneet Kaur, Deka, Rishi, Rose, Brent S, Panizzon, Matthew S, Hauger, Richard L, and Seibert, Tyler M
- Subjects
PROSTATE cancer ,MONOGENIC & polygenic inheritance (Genetics) ,CANCER diagnosis ,VETERANS ,RACE ,DISEASE risk factors - Abstract
Background Genetic scores may provide an objective measure of prostate cancer risk and thus inform screening decisions. We evaluated whether a polygenic hazard score based on 290 genetic variants (PHS290) is associated with prostate cancer risk in a diverse population, including Black men, who have higher average risk of prostate cancer death but are often treated as a homogeneously high-risk group. Methods This was a retrospective analysis of the Million Veteran Program, a national, population-based cohort study of US military veterans conducted 2011-2021. Cox proportional hazards analyses tested for association of genetic and other risk factors (including self-reported race and ethnicity and family history) with age at death from prostate cancer, age at diagnosis of metastatic (nodal or distant) prostate cancer, and age at diagnosis of any prostate cancer. Results A total of 590 750 male participants were included. Median age at last follow-up was 69 years. PHS290 was associated with fatal prostate cancer in the full cohort and for each racial and ethnic group (P < .001). Comparing men in the highest 20% of PHS290 with those in the lowest 20% (based on percentiles from an independent training cohort), the hazard ratio for fatal prostate cancer was 4.42 (95% confidence interval = 3.91 to 5.02). When accounting for guideline-recommended risk factors (family history, race, and ethnicity), PHS290 remained a strong independent predictor of any, metastatic, and fatal prostate cancer. Conclusions PHS290 stratified US veterans of diverse ancestry for lifetime risk of prostate cancer, including metastatic and fatal cancer. Predicting genetic risk of lethal prostate cancer with PHS290 might inform individualized decisions about prostate cancer screening. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Impact of Coronavirus Disease 2019 (COVID-19) Severity on Long-term Events in United States Veterans Using the Veterans Affairs Severity Index for COVID-19 (VASIC).
- Author
-
Galloway, Ashley, Park, Yojin, Tanukonda, Vidisha, Ho, Yuk-Lam, Nguyen, Xuan-Mai T, Maripuri, Monika, Dey, Andrew T, Gerlovin, Hanna, Posner, Daniel, Lynch, Kristine E, Cai, Tianxi, Luoh, Shiuh-Wen, Whitbourne, Stacey, Gagnon, David R, Muralidhar, Sumitra, Tsao, Phillip S, Casas, Juan P, Gaziano, J Michael, Wilson, Peter W F, and Hung, Adriana M
- Subjects
COVID-19 ,MYOCARDIAL infarction ,SARS disease ,VENOUS thrombosis ,COVID-19 pandemic ,VETERANS - Abstract
In this retrospective cohort study of 94 595 severe acute respiratory syndrome coronavirus 2–positive cases, we developed and validated an algorithm to assess the association between coronavirus disease 2019 (COVID-19) severity and long-term complications (stroke, myocardial infarction, pulmonary embolism/deep vein thrombosis, heart failure, and mortality). COVID-19 severity was associated with a greater risk of experiencing a long-term complication 31–120 days postinfection. Most incident events occurred 31–60 days postinfection and diminished after day 91, except heart failure for severe patients and death for moderate patients, which peaked on days 91–120. Understanding the differential impact of COVID-19 severity on long-term events provides insight into possible intervention modalities and critical prevention strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Influence of Long-term Nonaspirin NSAID Use on Risk of Frailty in Men ≥60 Years: The Physicians' Health Study.
- Author
-
Orkaby, Ariela R, Ward, Rachel, Chen, Jiaying, Shanbhag, Akshay, Sesso, Howard D, Gaziano, J Michael, Djousse, Luc, and Driver, Jane A
- Subjects
NONSTEROIDAL anti-inflammatory agents ,ACETAMINOPHEN ,ARTHRITIS Impact Measurement Scales ,RESEARCH funding ,PHYSICIANS ,LONGITUDINAL method - Abstract
Background: Inflammation is a central pathway leading to frailty but whether commonly used nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can prevent frailty is unknown.Methods: Prospective cohort study of male physicians ≥60 who participated in the Physicians' Health Study. Annual questionnaires collected data on NSAID use, lifestyle, and morbidity. Average annual NSAID use was categorized as 0 days/year, 1-12 days/year, 13-60 days/year, and >60 days/year. Frailty was assessed using a validated 33-item frailty index. Propensity score inverse probability of treatment weighting was used to address confounding by indication and logistic regression models estimated odds ratios (ORs) of prevalent frailty according to nonaspirin NSAID use.Results: A total of 12 101 male physicians were included (mean age 70 ± 7 years, mean follow-up 11 years). Reported NSAID use was 0 days/year for 2 234, 1-12 days/year for 5 812, 13-60 days/year for 2 833, and >60 days/year for 1 222 participants. A total of 2 413 participants (20%) were frail. Higher self-reported NSAID use was associated with greater alcohol use, smoking, arthritis, hypertension, and heart disease, while less NSAID use was associated with coumadin use and prior bleeding. After propensity score adjustment, all characteristics were balanced. ORs (95% confidence intervals) of prevalent frailty were 0.90 (0.80-1.02), 1.02 (0.89-1.17), and 1.26 (1.07-1.49) for average NSAID use of 1-12 days/year, 13-60 days/year, and >60 days/year, compared to 0 days/year (p-trend < .001).Conclusions: Long-term use of NSAIDs at high frequency is associated with increased risk of frailty among older men. Additional study is needed to understand the role of anti-inflammatory medication in older adults and its implication for overall health. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Frailty and cardiovascular mortality in more than 3 million US Veterans.
- Author
-
Shrauner, William, Lord, Emily M, Nguyen, Xuan-Mai T, Song, Rebecca J, Galloway, Ashley, Gagnon, David R, Driver, Jane A, Gaziano, J Michael, Wilson, Peter W F, Djousse, Luc, Cho, Kelly, and Orkaby, Ariela R
- Subjects
FRAGILITY (Psychology) ,CARDIOVASCULAR diseases ,MORTALITY ,AGING ,REVASCULARIZATION (Surgery) - Abstract
Aims Frailty is associated with an increased risk of all-cause mortality and cardiovascular (CV) events. Limited data exist from the modern era of CV prevention on the relationship between frailty and CV mortality. We hypothesized that frailty is associated with an increased risk of CV mortality. Methods and results All US Veterans aged ≥65 years who were regular users of Veteran Affairs care from 2002 to 2017 were included. Frailty was defined using a 31-item previously validated frailty index, ranging from 0 to 1. The primary outcome was CV mortality with secondary analyses examining the relationship between frailty and CV events (myocardial infarction, stroke, revascularization). Survival analysis models were adjusted for age, sex, ethnicity, geographic region, smoking, hyperlipidaemia, statin use, and blood pressure medication use. There were 3 068 439 US Veterans included in the analysis. Mean age was 74.1 ± 5.8 years in 2002, 76.0 ± 8.3 years in 2014, 98% male, and 87.5% White. In 2002, the median (interquartile range) frailty score was 0.16 (0.10–0.23). This increased and stabilized to 0.19 (0.10–0.32) for 2006–14. The presence of frailty was associated with an increased risk of CV mortality at every stage of frailty. Frailty was associated with an increased risk of myocardial infarction and stroke, but not revascularization. Conclusion In this population, both the presence and severity of frailty are tightly correlated with CV death, independent of underlying CV disease. This study is the largest and most contemporary evaluation of the relationship between frailty and CV mortality to date. Further work is needed to understand how this risk can be diminished. Key Question Can an electronic frailty index identify adults aged 65 and older who are at risk of CV mortality and major CV events? Key Finding Among 3 068 439 US Veterans aged 65 and older, frailty was associated with an increased risk of CV mortality at every level of frailty. Frailty was also associated with an increased risk of myocardial infarction and stroke, but not revascularization. Take Home Message Both the presence and severity of frailty are associated with CV mortality and major CV events, independent of underlying CV disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Trajectories of Frailty in the 5 Years Prior to Death Among U.S. Veterans Born 1927-1934.
- Author
-
Ward, Rachel E, Orkaby, Ariela R, Dumontier, Clark, Charest, Brian, Hawley, Chelsea E, Yaksic, Enzo, Quach, Lien, Kim, Dae H, Gagnon, David R, Gaziano, J Michael, Cho, Kelly, Djousse, Luc, Driver, Jane A, and Henderson, Chelsea E
- Subjects
FRAILTY ,VETERANS ,HEALTH insurance ,INSURANCE claims ,GERIATRIC assessment ,RESEARCH ,RETROSPECTIVE studies ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding - Abstract
Background: Electronic frailty indices (eFIs) are increasingly used to identify patients at risk for morbidity and mortality. Whether eFIs capture the spectrum of frailty change, including decline, stability, and improvement, is unknown.Methods: In a nationwide retrospective birth cohort of U.S. Veterans, a validated eFI, including 31 health deficits, was calculated annually using medical record and insurance claims data (2002-2012). K-means clustering was used to assign patients into frailty trajectories measured 5 years prior to death.Results: There were 214 250 veterans born between 1927 and 1934 (mean [SD] age at death = 79.4 [2.8] years, 99.2% male, 90.3% White) with an annual eFI in the 5 years before death. Nine frailty trajectories were identified. Those starting at nonfrail or prefrail had 2 stable trajectories (nonfrail to prefrail, n = 29 786 and stable prefrail, n = 28 499) and 2 rapidly increasing trajectories (prefrail to moderately frail, n = 28 244 and prefrail to severely frail, n = 22 596). Those who were mildly frail at baseline included 1 gradually increasing trajectory (mildly to moderately frail, n = 33 806) and 1 rapidly increasing trajectory (mildly to severely frail, n = 15 253). Trajectories that started at moderately or severely frail included 2 gradually increasing trajectories (moderately to severely frail, n = 27 662 and progressing severely frail, n = 14 478) and 1 recovering trajectory (moderately frail to mildly frail, n = 13 926).Conclusions: Nine frailty trajectories, including 1 recovering trajectory, were identified in this cohort of older U.S. Veterans. Future work is needed to understand whether prevention and treatment strategies can improve frailty trajectories and contribute to compression of morbidity toward the end of life. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans.
- Author
-
Gerlovin, Hanna, Posner, Daniel C, Ho, Yuk-Lam, Rentsch, Christopher T, Tate, Janet P, King, Joseph T, Kurgansky, Katherine E, Danciu, Ioana, Costa, Lauren, Linares, Franciel A, Goethert, Ian D, Jacobson, Daniel A, Freiberg, Matthew S, Begoli, Edmon, Muralidhar, Sumitra, Ramoni, Rachel B, Tourassi, Georgia, Gaziano, J Michael, Justice, Amy C, and Gagnon, David R
- Subjects
COVID-19 ,COMBINATION drug therapy ,CONFIDENCE intervals ,PHARMACOLOGY ,INTUBATION ,MACHINE learning ,TREATMENT effectiveness ,HOSPITAL care of older people ,SURVIVAL analysis (Biometry) ,DESCRIPTIVE statistics ,HYDROXYCHLOROQUINE ,AZITHROMYCIN ,VETERANS ,ELECTRONIC health records ,PROPORTIONAL hazards models ,THERAPEUTICS - Abstract
Hydroxychloroquine (HCQ) was proposed as an early therapy for coronavirus disease 2019 (COVID-19) after in vitro studies indicated possible benefit. Previous in vivo observational studies have presented conflicting results, though recent randomized clinical trials have reported no benefit from HCQ among patients hospitalized with COVID-19. We examined the effects of HCQ alone and in combination with azithromycin in a hospitalized population of US veterans with COVID-19, using a propensity score–adjusted survival analysis with imputation of missing data. According to electronic health record data from the US Department of Veterans Affairs health care system, 64,055 US Veterans were tested for the virus that causes COVID-19 between March 1, 2020 and April 30, 2020. Of the 7,193 veterans who tested positive, 2,809 were hospitalized, and 657 individuals were prescribed HCQ within the first 48-hours of hospitalization for the treatment of COVID-19. There was no apparent benefit associated with HCQ receipt, alone or in combination with azithromycin, and there was an increased risk of intubation when HCQ was used in combination with azithromycin (hazard ratio = 1.55; 95% confidence interval: 1.07, 2.24). In conclusion, we assessed the effectiveness of HCQ with or without azithromycin in treatment of patients hospitalized with COVID-19, using a national sample of the US veteran population. Using rigorous study design and analytic methods to reduce confounding and bias, we found no evidence of a survival benefit from the administration of HCQ. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma.
- Author
-
Fillmore, Nathanael R, DuMontier, Clark, Yildirim, Cenk, La, Jennifer, Epstein, Mara M, Cheng, David, Cirstea, Diana, Yellapragada, Sarvari, Abel, Gregory A, Gaziano, J Michael, Do, Nhan, Brophy, Mary, Kim, Dae H, Munshi, Nikhil C, Driver, Jane A, and Fillmore, Nathanael
- Subjects
MULTIPLE myeloma ,COMORBIDITY ,OLDER people ,VETERANS ,OVERALL survival ,CARDIOVASCULAR diseases ,METABOLIC disorders ,MULTIPLE myeloma treatment ,RESEARCH ,RESEARCH methodology ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding - Abstract
Background: Traditional count-based measures of comorbidity are unlikely to capture the complexity of multiple chronic conditions (multimorbidity) in older adults with cancer. We aimed to define patterns of multimorbidity and their impact in older United States veterans with multiple myeloma (MM).Methods: We measured 66 chronic conditions in 5076 veterans aged 65 years and older newly treated for MM in the national Veterans Affairs health-care system from 2004 to 2017. Latent class analysis was used to identify patterns of multimorbidity among these conditions. These patterns were then assessed for their association with overall survival, our primary outcome. Secondary outcomes included emergency department visits and hospitalizations.Results: Five patterns of multimorbidity emerged from the latent class analysis, and survival varied across these patterns (log-rank 2-sided P < .001). Older veterans with cardiovascular and metabolic disease (30.9%, hazard ratio [HR] = 1.33, 95% confidence interval [CI] = 1.21 to 1.45), psychiatric and substance use disorders (9.7%, HR = 1.58, 95% CI = 1.39 to 1.79), chronic lung disease (15.9%, HR = 1.69, 95% CI = 1.53 to 1.87), and multisystem impairment (13.8%, HR = 2.25, 95% CI = 2.03 to 2.50) had higher mortality compared with veterans with minimal comorbidity (29.7%, reference). Associations with mortality were maintained after adjustment for sociodemographic variables, measures of disease risk, and the count-based Charlson Comorbidity Index. Multimorbidity patterns were also associated with emergency department visits and hospitalizations.Conclusions: Our findings demonstrate the need to move beyond count-based measures of comorbidity and consider cancer in the context of multiple chronic conditions. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. Updating and Validating the U.S. Veterans Affairs Frailty Index: Transitioning From ICD-9 to ICD-10.
- Author
-
Cheng, David, DuMontier, Clark, Yildirim, Cenk, Charest, Brian, Hawley, Chelsea E, Zhuo, Min, Paik, Julie M, Yaksic, Enzo, Gaziano, J Michael, Do, Nhan, Brophy, Mary, Cho, Kelly, Kim, Dae H, Driver, Jane A, Fillmore, Nathanael R, Orkaby, Ariela R, Hawley, Chelsea, Paik, Julie, and Fillmore, Nathanael
- Subjects
FRAIL elderly ,VETERANS ,NOSOLOGY ,ELECTRONIC health records ,PREDICTIVE validity ,TEST validity ,RESEARCH ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding - Abstract
Background: The Veterans Affairs Frailty Index (VA-FI) is an electronic frailty index developed to measure frailty using administrative claims and electronic health records data in Veterans. An update to ICD-10 coding is needed to enable contemporary measurement of frailty.Method: International Classification of Diseases, ninth revision (ICD-9) codes from the original VA-FI were mapped to ICD-10 first using the Centers for Medicaid and Medicare Services (CMS) General Equivalence Mappings. The resulting ICD-10 codes were reviewed by 2 geriatricians. Using a national cohort of Veterans aged 65 years and older, the prevalence of deficits contributing to the VA-FI and associations between the VA-FI and mortality over years 2012-2018 were examined.Results: The updated VA-FI-10 includes 6422 codes representing 31 health deficits. Annual cohorts defined on October 1 of each year included 2 266 191 to 2 428 115 Veterans, for which the mean age was 76 years, 97%-98% were male, 78%-79% were White, and the mean VA-FI was 0.20-0.22. The VA-FI-10 deficits showed stability before and after the transition to ICD-10 in 2015, and maintained strong associations with mortality. Patients classified as frail (VA-FI > 0.2) consistently had a hazard of death more than 2 times higher than nonfrail patients (VA-FI ≤ 0.1). Distributions of frailty and associations with mortality varied with and without linkage to CMS data and with different assessment periods for capturing deficits.Conclusions: The updated VA-FI-10 maintains content validity, stability, and predictive validity for mortality in a contemporary cohort of Veterans aged 65 years and older, and may be applied to ICD-9 and ICD-10 claims data to measure frailty. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. Association Between Long-Term Aspirin Use and Frailty in Men: The Physicians' Health Study.
- Author
-
Orkaby, Ariela R, Yang, Laiji, Dufour, Alyssa B, Travison, Thomas G, Sesso, Howard D, Driver, Jane A, Djousse, Luc, and Gaziano, J Michael
- Subjects
ASPIRIN ,MEN'S health ,OLDER men ,CARDIOVASCULAR diseases ,HEALTH behavior - Abstract
Background Chronic inflammation may lead to frailty, however the potential for anti-inflammatory medications such as aspirin to prevent frailty is unknown. We sought to examine the association between long-term aspirin use and prevalent frailty. Methods We included 12 101 men ≥60 years who participated in the Physicians' Health Study I, a completed aspirin randomized controlled trial (1982–1989). Annual questionnaires collected self-reported data on daily aspirin use, lifestyle, and clinical variables. Average aspirin use was summed into 2 categories: ≤60 days/year and >60 days/year. Frailty was assessed using a 33-item index 11 years after trial completion. A score of ≥0.21 was considered frail. Propensity score inverse probability of treatment weighting was used for statistical control of confounding. Logistic regression models estimated odds of frailty as a function of categories of average aspirin use. Results Mean age was 70.5 years (range 60–101). Following an average of 11 ± 0.6 years of follow-up, aspirin use was reported as ≤60 days/year for 15%; 2413 participants (20%) were frail. Frequency of aspirin use was associated with smoking, alcohol consumption, hypertension, and cardiovascular disease, but negatively associated with bleeding and Coumadin use. The odds ratio (95% confidence intervals) for frailty was 0.85 (0.76–0.96) for average aspirin use >60 days/year versus aspirin use ≤60 days/year. Results were similar using an alternate definition of frailty. Conclusions Long-term regular aspirin use is inversely associated with frailty among older men, even after consideration of multimorbidity and health behaviors. Work is needed to understand the role of medications with anti-inflammatory properties on aging. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Understanding the use of observational and randomized data in cardiovascular medicine.
- Author
-
Bowman, Louise, Baras, Aris, Bombien, René, Califf, Robert M, Chen, Zhengmin, Gale, Chris P, Gaziano, J Michael, Grobbee, Diederick E, Maggioni, Aldo P, Muse, Evan D, Roden, Dan M, Schroeder, Stefan, Wallentin, Lars, and Casadei, Barbara
- Abstract
The availability of large datasets from multiple sources [e.g. registries, biobanks, electronic health records (EHRs), claims or billing databases, implantable devices, wearable sensors, and mobile apps], coupled with advances in computing and analytic technologies, have provided new opportunities for conducting innovative health research. Equally, improved digital access to health information has facilitated the conduct of efficient randomized controlled trials (RCTs) upon which clinical management decisions can be based, for instance, by permitting the identification of eligible patients for recruitment and/or linkage for follow-up via their EHRs. Given these advances in cardiovascular data science and the complexities they behold, it is important that health professionals have clarity on the appropriate use and interpretation of observational, so-called 'real-world', and randomized data in cardiovascular medicine. The Cardiovascular Roundtable of the European Society of Cardiology (ESC) held a workshop to explore the future of RCTs and the current and emerging opportunities for gathering and exploiting complex observational datasets in cardiovascular research. The aim of this article is to provide a perspective on the appropriate use of randomized and observational data and to outline the ESC plans for supporting the collection and availability of clinical data to monitor and improve the quality of care of patients with cardiovascular disease in Europe and provide an infrastructure for undertaking pragmatic RCTs. Moreover, the ESC continues to campaign for greater engagement amongst regulators, industry, patients, and health professionals in the development and application of a more efficient regulatory framework that is able to take maximal advantage of new opportunities for improving the design and efficiency of observational studies and RCT in patients with cardiovascular disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies.
- Author
-
McGee, Emma E, Jackson, Sarah S, Petrick, Jessica L, Dyke, Alison L Van, Adami, Hans-Olov, Albanes, Demetrius, Andreotti, Gabriella, Beane-Freeman, Laura E, Gonzalez, Amy Berrington de, Buring, Julie E, Chan, Andrew T, Chen, Yu, Fraser, Gary E, Freedman, Neal D, Gao, Yu-Tang, Gapstur, Susan M, Gaziano, J Michael, Giles, Graham G, Grant, Eric J, and Grodstein, Francine
- Subjects
BILIARY tract cancer ,GALLBLADDER cancer ,SMOKING ,CANCER risk factors ,ALCOHOL drinking - Abstract
Background: Tobacco and alcohol are well-established risk factors for numerous cancers, yet their relationship to biliary tract cancers remains unclear.Methods: We pooled data from 26 prospective studies to evaluate associations of cigarette smoking and alcohol consumption with biliary tract cancer risk. Study-specific hazard ratios (HRs) and 95% confidence intervals (CIs) for associations with smoking and alcohol consumption were calculated. Random-effects meta-analysis produced summary estimates. All statistical tests were two-sided.Results: Over a period of 38 369 156 person-years of follow-up, 1391 gallbladder, 758 intrahepatic bile duct, 1208 extrahepatic bile duct, and 623 ampulla of Vater cancer cases were identified. Ever, former, and current smoking were associated with increased extrahepatic bile duct and ampulla of Vater cancers risk (eg, current vs never smokers HR = 1.69, 95% CI = 1.34 to 2.13 and 2.22, 95% CI = 1.69 to 2.92, respectively), with dose-response effects for smoking pack-years, duration, and intensity (all Ptrend < .01). Current smoking and smoking intensity were also associated with intrahepatic bile duct cancer (eg, >40 cigarettes per day vs never smokers HR = 2.15, 95 % CI = 1.15 to 4.00; Ptrend = .001). No convincing association was observed between smoking and gallbladder cancer. Alcohol consumption was only associated with intrahepatic bile duct cancer, with increased risk for individuals consuming five or more vs zero drinks per day (HR = 2.35, 95%CI = 1.46 to 3.78; Ptrend = .04). There was evidence of statistical heterogeneity among several cancer sites, particularly between gallbladder cancer and the other biliary tract cancers.Conclusions: Smoking appears to increase the risk of developing all biliary tract cancers except gallbladder cancer. Alcohol may increase the risk of intrahepatic bile duct cancer. Findings highlight etiologic heterogeneity across the biliary tract. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
16. High-throughput multimodal automated phenotyping (MAP) with application to PheWAS.
- Author
-
Liao, Katherine P, Sun, Jiehuan, Cai, Tianrun A, Link, Nicholas, Hong, Chuan, Huang, Jie, Huffman, Jennifer E, Gronsbell, Jessica, Zhang, Yichi, Ho, Yuk-Lam, Castro, Victor, Gainer, Vivian, Murphy, Shawn N, O'Donnell, Christopher J, Gaziano, J Michael, Cho, Kelly, Szolovits, Peter, Kohane, Isaac S, Yu, Sheng, and Cai, Tianxi
- Abstract
Objective: Electronic health records linked with biorepositories are a powerful platform for translational studies. A major bottleneck exists in the ability to phenotype patients accurately and efficiently. The objective of this study was to develop an automated high-throughput phenotyping method integrating International Classification of Diseases (ICD) codes and narrative data extracted using natural language processing (NLP).Materials and Methods: We developed a mapping method for automatically identifying relevant ICD and NLP concepts for a specific phenotype leveraging the Unified Medical Language System. Along with health care utilization, aggregated ICD and NLP counts were jointly analyzed by fitting an ensemble of latent mixture models. The multimodal automated phenotyping (MAP) algorithm yields a predicted probability of phenotype for each patient and a threshold for classifying participants with phenotype yes/no. The algorithm was validated using labeled data for 16 phenotypes from a biorepository and further tested in an independent cohort phenome-wide association studies (PheWAS) for 2 single nucleotide polymorphisms with known associations.Results: The MAP algorithm achieved higher or similar AUC and F-scores compared to the ICD code across all 16 phenotypes. The features assembled via the automated approach had comparable accuracy to those assembled via manual curation (AUCMAP 0.943, AUCmanual 0.941). The PheWAS results suggest that the MAP approach detected previously validated associations with higher power when compared to the standard PheWAS method based on ICD codes.Conclusion: The MAP approach increased the accuracy of phenotype definition while maintaining scalability, thereby facilitating use in studies requiring large-scale phenotyping, such as PheWAS. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
17. The Burden of Frailty Among U.S. Veterans and Its Association With Mortality, 2002-2012.
- Author
-
Orkaby, Ariela R, Nussbaum, Lisa, Ho, Yuk-Lam, Gagnon, David, Quach, Lien, Ward, Rachel, Quaden, Rachel, Yaksic, Enzo, Harrington, Kelly, Paik, Julie M, Kim, Dae H, Wilson, Peter W, Gaziano, J Michael, Djousse, Luc, Cho, Kelly, Driver, Jane A, and Gaziano, Michael J
- Subjects
MORTALITY ,VETERANS ,BLACK men ,LIFE expectancy ,SURVIVAL analysis (Biometry) - Abstract
Background: Frailty is a key determinant of clinical outcomes. We sought to describe frailty among U.S. Veterans and its association with mortality.Methods: Nationwide retrospective cohort study of regular Veterans Affairs (VA) users, aged at least 65 years in 2002-2012, followed through 2014, using national VA administrative and Medicare and Medicaid data. A frailty index (FI) for VA (VA-FI) was calculated using the cumulative deficit method. Thirty-one age-related deficits in health from diagnostic and procedure codes were included and were updated biennially. Survival analysis assessed associations between VA-FI and mortality.Results: A VA-FI was calculated for 2,837,152 Veterans over 10 years. In 2002, 35.5% were non-frail (FI = 0-0.10), 32.6% were pre-frail (FI = 0.11-0.20), 18.9% were mildly frail (FI = 0.21-0.30), 8.7% were moderately frail (FI = 0.31-0.40), and 4.3% were severely frail (FI > 0.40). From 2002 to 2012, the prevalence of moderate frailty increased to 12.7%and severe frailty to 14.1%. Frailty was strongly associated with survival and was independent of age, sex, race, and smoking; the VA-FI better predicted mortality than age alone. Although prevalence of frailty rose over time, compared to non-frail Veterans, 2 years' hazard ratios (95% confidence intervals) for mortality declined from a peak in 2004 of 2.01 (1.97-2.04), 3.49 (3.44-3.55), 5.88 (5.79-5.97), and 10.39 (10.23-10.56) for pre-frail, mildly, moderately, and severely frail, respectively, to 1.51 (1.49-1.53), 2.36 (2.33-2.39), 3.68 (3.63-3.73), 6.62 (6.53-6.71) in 2012. At every frailty level, risk of mortality was lower for women versus men and higher for blacks versus whites.Conclusions: Frailty affects at least 3 of every 10 U.S. Veterans aged 65 years and older, and is strongly associated with mortality. The VA-FI could be used to more accurately estimate life expectancy and individualize care for Veterans. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
18. Interactions Between Genome-Wide Significant Genetic Variants and Circulating Concentrations of 25-Hydroxyvitamin D in Relation to Prostate Cancer Risk in the National Cancer Institute BPC3.
- Author
-
Dimitrakopoulou, Vasiliki I., Travis, Ruth C., Shui, Irene M., Mondul, Alison, Albanes, Demetrius, Virtamo, Jarmo, Agudo, Antonio, Boeing, Heiner, Bueno-de-Mesquita, H. Bas, Gunter, Marc J., Johansson, Mattias, Kay-Tee Khaw, Overvad, Kim, Palli, Domenico, Trichopoulou, Antonia, Giovannucci, Edward, Hunter, David J., Lindström, Sara, Willett, Walter, and Gaziano, J. Michael
- Subjects
ALLELES ,CONFIDENCE intervals ,GENETIC polymorphisms ,HUMAN genome ,LONGITUDINAL method ,PROBABILITY theory ,STATISTICS ,PROSTATE tumors ,VITAMIN D ,LOGISTIC regression analysis ,DATA analysis ,CASE-control method ,DATA analysis software ,DESCRIPTIVE statistics ,SEQUENCE analysis ,ODDS ratio ,GENOTYPES ,GENETICS ,TUMOR risk factors - Abstract
Genome-wide association studies (GWAS) have identified over 100 single nucleotide polymorphisms (SNPs) associated with prostate cancer. However, information on the mechanistic basis for some associations is limited. Recent research has been directed towards the potential association of vitamin D concentrations and prostate cancer, but little is known about whether the aforementioned genetic associations are modified by vitamin D. We investigated the associations of 46 GWAS-identified SNPs, circulating concentrations of 25-hydroxyvitamin D (25 (OH)D), and prostate cancer (3,811 cases, 511 of whom died from the disease, compared with 2,980 controls--from 5 cohort studies that recruited participants over several periods beginning in the 1980s). We used logistic regression models with data from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) to evaluate interactions on the multiplicative and additive scales. After allowing for multiple testing, none of the SNPs examined was significantly associated with 25(OH)D concentration, and the SNP-prostate cancer associations did not differ by these concentrations. A statistically significant interaction was observed for each of 2 SNPs in the 8q24 region (rs620861 and rs16902094), 25(OH)D concentration, and fatal prostate cancer on both multiplicative and additive scales (P ≤ 0.001). We did not find strong evidence that associations between GWAS-identified SNPs and prostate cancer are modified by circulating concentrations of 25(OH)D. The intriguing interactions between rs620861 and rs16902094,25(OH)D concentration, and fatal prostate cancer warrant replication. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. Anthropometry and head and neck cancer:a pooled analysis of cohort data.
- Author
-
Gaudet, Mia M, Kitahara, Cari M, Newton, Christina C, Bernstein, Leslie, Reynolds, Peggy, Weiderpass, Elisabete, Kreimer, Aimée R, Yang, Gong, Adami, Hans-Olov, Alavanja, Michael C, Beane Freeman, Laura E, Boeing, Heiner, Buring, Julie, Chaturvedi, Anil, Chen, Yu, D'Aloisio, Aimee A, Freedman, Michal, Gao, Yu-Tang, Gaziano, J Michael, and Giles, Graham G
- Abstract
Background: Associations between anthropometry and head and neck cancer (HNC) risk are inconsistent. We aimed to evaluate these associations while minimizing biases found in previous studies.Methods: We pooled data from 1,941,300 participants, including 3760 cases, in 20 cohort studies and used multivariable-adjusted Cox proportional hazard regression models to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of anthropometric measures with HNC risk overall and stratified by smoking status.Results: Greater waist circumference (per 5 cm: HR = 1.04, 95% CI 1.03-1.05, P-value for trend = <0.0001) and waist-to-hip ratio (per 0.1 unit: HR = 1.07, 95% CI 1.05-1.09, P-value for trend = <0.0001), adjusted for body mass index (BMI), were associated with higher risk and did not vary by smoking status (P-value for heterogeneity = 0.85 and 0.44, respectively). Associations with BMI (P-value for interaction = <0.0001) varied by smoking status. Larger BMI was associated with higher HNC risk in never smokers (per 5 kg/m(2): HR = 1.15, 95% CI 1.06-1.24, P-value for trend = 0.0006), but not in former smokers (per 5 kg/m(2): HR = 0.99, 95% CI 0.93-1.06, P-value for trend = 0.79) or current smokers (per 5 kg/m(2): HR = 0.76, 95% CI 0.71-0.82, P-value for trend = <0.0001). Larger hip circumference was not associated with a higher HNC risk. Greater height (per 5 cm) was associated with higher risk of HNC in never and former smokers, but not in current smokers.Conclusions: Waist circumference and waist-to-hip ratio were associated positively with HNC risk regardless of smoking status, whereas a positive association with BMI was only found in never smokers. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
20. Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival.
- Author
-
Yin Cao, Lindström, Sara, Schumaciier, Fredrick, Stevens, Victoria L., Albanes, Demetrius, Berndt, Sonja I., Boeing, Heiner, Bas Bueno-de-Mesquita, H., Canzian, Federico, Chamosa, Saioa, Chanock, Stephen J., Diver, W. Ryan, Gapstur, Susan M., Gaziano, J. Michael, Giovannucci, Edward L., Haiman, Christopher A., Henderson, Brian, Johansson, Mattias, Le Marchand, Loïc, and Palli, Domenico
- Subjects
SOMATOMEDIN ,GENETIC polymorphism research ,CANCER invasiveness ,PROSTATE cancer prognosis ,PROSTATE cancer & genetics - Abstract
Background The insulin-like growth factor (IGF) signaling pathway has been implicated in prostate cancer (PCa) initiation, but its role in progression remains unknown. Methods Among 5887 PCa patients (704 PCa deaths) of European ancestry from seven cohorts in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium, we conducted Cox kernel machine pathway analysis to evaluate whether 530 tagging single nucleotide polymorphisms (SNPs) in 26 IGF pathway-related genes were collectively associated with PCa mortality. We also conducted SNP-specific analysis using stratified Cox models adjusting for multiple testing. In 2424 patients (313 PCa deaths), we evaluated the association of prediagnostic circulating IGF1 and IGFBP3 levels and PCa mortality. All statistical tests were two-sided. Results The IGF signaling pathway was associated with PCa mortality (P= .03), and IGF2-AS and SSTR2 were the main contributors (both P= .04). In SNP-specific analysis, 36 SNPs were associated with PCa mortality with P
trend less than .05, but only three SNPs in the IGF2-AS remained statistically significant after gene-based corrections. Two were in linkage disequilibrium (r²= 1 for rs1004446 and rs3741211), whereas the third, rs4366464, was independent (r² = 0.03).The hazard ratios (HRs) per each additional risk allele were 1.19 (95% confidence interval [CI] = 1.06 to 1.34; Ptrend = -003) for rs3741211 and 1.44 (95% CI = 1,20 to 1.73; Ptrends < .001) for rs4366464. rs4366464 remained statistically significant after correction for all SNPs (Ptrend.corr = -04). Prediagnostic IGF1 (HRhighest vs lowest quartile = 0-71; 95% CI = 0.48 to 1.04) and IGFBP3 (HR = 0.93; 95% CI = 0.65 to 1.34) levels were not associated with PCa mortality. Conclusions The IGF signaling pathway, primarily IGF2-AS and SSTR2 genes, may be important in PCa survival. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
21. Anthropometric and Hormonal Risk Factors for Male Breast Cancer: Male Breast Cancer Pooling Project Results.
- Author
-
Brinton, Louise A., Cook, Michael B., McCormack, Valerie, Johnson, Kenneth C., Olsson, Håkan, Casagrande, JohnT., Cooke, Rosie, Falk, Roni T., Gapstur, Susan M., Gaudet, Mia M., Gaziano, J. Michael, Gkiokas, Georgios, Guénel, Pascal, Henderson, Brian E., Hollenbeck, Albert, Hsing, Ann W., Kolonel, Laurence N., Isaacs, Claudine, Lubin, Jay H., and Michels, Karin B.
- Subjects
BREAST cancer ,MEN'S health ,ETIOLOGY of diseases ,BODY weight -- Risk factors ,BREAST diseases - Abstract
Background The etiology of male breast cancer is poorly understood, partly because of its relative rarity. Although genetic factors are involved, less is known regarding the role of anthropometric and hormonally related risk factors. Methods In the Male Breast Cancer Pooling Project, a consortium of 11 case-control and 10 cohort investigations involving 2405 case patients (n = 1190 from case-control and n = 1215 from cohort studies) and 52013 control subjects, individual participant data were harmonized and pooled. Unconditional logistic regression generated study design-specific (case-control/cohort) odds ratios (ORs) and 95% confidence intervals (CIs), with exposure estimates combined using fixed effects meta-analysis. All statistical tests were two-sided. Results Risk was statistically significantly associated with weight (highest/lowest tertile: OR = 1.36; 95% CI = 1.18 to 1.57), height (OR = 1.18; 95% CI = 1.01 to 1.38), and body mass index (BMI; OR = 1.30; 95% CI = 1.12 to 1.51 ), with evidence that recent rather than distant BMI was the strongest predictor. Klinefelter syndrome (OR = 24.7; 95% CI = 8.94 to 68.4) and gynecomastia (OR = 9.78; 95% CI = 7.52 to 12.7) were also statistically significantly associated with risk, relations that were independent of BMI. Diabetes also emerged as an independent risk factor (OR = 1.19; 95% CI = 1.04 to 1.37). There were also suggestive relations with cryptorchidism (OR = 2.18; 95% CI = 0.96 to 4.94) and orchitis (OR = 1.43; 95% CI = 1.02 to 1.99). Although age at onset of puberty and histories of infertility were unrelated to risk, never having had children was statistically significantly related (OR = 1.29; 95% CI = 1.01 to 1.66). Among individuals diagnosed at older ages, a history of fractures was statistically significantly related (OR = 1.41; 95% CI = 1.07 to 1.86). Conclusions Consistent findings across case-control and cohort investigations, complemented by pooled analyses, indicated important roles for anthropometric and hormonal risk factors in the etiology of male breast cancer. Further investigation should focus on potential roles of endogenous hormones. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
22. Corrigendum to: Updating and Validating the U.S. Veterans Affairs Frailty Index: Transitioning From ICD-9 to ICD-10.
- Author
-
Cheng, David, DuMontier, Clark, Yildirim, Cenk, Charest, Brian, Hawley, Chelsea E, Zhuo, Min, Paik, Julie M, Yaksic, Enzo, Gaziano, J Michael, Do, Nhan, Brophy, Mary, Cho, Kelly, Kim, Dae H, Driver, Jane A, Fillmore, Nathanael R, and Orkaby, Ariela R
- Subjects
INTERNATIONAL Statistical Classification of Diseases & Related Health Problems ,FRAILTY ,VETERANS - Abstract
In the article "Updating and Validating the U.S. Veterans Affairs Frailty Index: Transitioning From ICD-9 to ICD-10", the link to the data in the Supplementary data file was inadvertently missed. Author notes Footnotes 1 Co-first authors. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
23. Association of Type 2 Diabetes Susceptibility Variants With Advanced Prostate Cancer Risk in the Breast and Prostate Cancer Cohort Consortium.
- Author
-
Machiela, Mitchell J., Lindström, Sara, Allen, Naomi E., Haiman, Christopher A., Albanes, Demetrius, Barricade, Aurelio, Berndt, Sonja I., Bueno-De-Mesquita, H. Bas, Chanock, Stephen, Gaziano, J. Michael, Gapstur, Susan M., Giovannucci, Edward, Henderson, Brian E., Jacobs, Eric J., Kolonel, Laurence N., Krogh, Vittorio, Jing Ma, Stampfer, Meir J., Stevens, Victoria L., and Stram, Daniel O.
- Subjects
TYPE 2 diabetes risk factors ,PROSTATE tumors ,CONFIDENCE intervals ,STATISTICAL correlation ,DATABASES ,DISEASE susceptibility ,EPIDEMIOLOGY ,GENETIC polymorphisms ,MEDICAL information storage & retrieval systems ,RESEARCH funding ,GENETIC markers ,LOGISTIC regression analysis ,GENOMICS ,DATA analysis ,CONTROL groups ,GENETICS - Abstract
Observational studies have found an inverse association between type 2 diabetes (T2D) and prostate cancer (PCa), and genome-wide association studies have found common variants near 3 loci associated with both diseases. The authors examined whether a genetic background that favors T2D is associated with risk of advanced PCa. Data from the National Cancer Institute's Breast and Prostate Cancer Cohort Consortium, a genome-wide association study of 2,782 advanced PCa cases and 4,458 controls, were used to evaluate whether individual single nucleotide polymorphisms or aggregations of these 36 T2D susceptibility loci are associated with PCa. Ten T2D markers near 9 loci (NOTCH2, ADCY5, JAZF1, CDKN2A/B, TCF7L2, KCNQ1, MTNRIB, FTO, and HNFIB) were nominally associated with PCa (P< 0.05); the association for single nucleotide polymorphism rs757210 at the HNFIB locus was significant when multiple comparisons were accounted for (adjusted P= 0.001). Genetic risk scores weighted by the T2D log odds ratio and multilocus kernel tests also indicated a significant relation between T2D variants and PCa risk. A mediation analysis of 9,065 PCa cases and 9,526 controls failed to produce evidence that diabetes mediates the association of the HNF1B locus with PCa risk. These data suggest a shared genetic component between T2D and PCa and add to the evidence for an interrelation between these diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
24. Plasma Adiponectin and the Risk of Hypertension in White and Black Postmenopausal Women.
- Author
-
Wang, Lu, Manson, JoAnn E., Gaziano, J. Michael, Liu, Simin, Cochrane, Barbara, Cook, Nancy R., Ridker, Paul M., Rifai, Nader, and Sesso, Howard D.
- Published
- 2012
- Full Text
- View/download PDF
25. Association between adult height, genetic susceptibility and risk of glioma.
- Author
-
Kitahara, Cari M, Wang, Sophia S, Melin, Beatrice S, Wang, Zhaoming, Braganza, Melissa, Inskip, Peter D, Albanes, Demetrius, Andersson, Ulrika, Beane Freeman, Laura E, Buring, Julie E, Carreón, Tania, Feychting, Maria, Gapstur, Susan M, Gaziano, J Michael, Giles, Graham G, Hallmans, Goran, Hankinson, Susan E, Henriksson, Roger, Hsing, Ann W, and Johansen, Christoffer
- Subjects
DISEASE susceptibility ,GLIOMAS ,SCIENTIFIC observation ,LONGITUDINAL method ,ESTIMATION theory ,LOGISTIC regression analysis ,DISEASE risk factors - Abstract
Background Some, but not all, observational studies have suggested that taller stature is associated with a significant increased risk of glioma. In a pooled analysis of observational studies, we investigated the strength and consistency of this association, overall and for major sub-types, and investigated effect modification by genetic susceptibility to the disease.Methods We standardized and combined individual-level data on 1354 cases and 4734 control subjects from 13 prospective and 2 case–control studies. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for glioma and glioma sub-types were estimated using logistic regression models stratified by sex and adjusted for birth cohort and study. Pooled ORs were additionally estimated after stratifying the models according to seven recently identified glioma-related genetic variants.Results Among men, we found a positive association between height and glioma risk (≥190 vs 170–174 cm, pooled OR = 1.70, 95% CI: 1.11–2.61; P-trend = 0.01), which was slightly stronger after restricting to cases with glioblastoma (pooled OR = 1.99, 95% CI: 1.17–3.38; P-trend = 0.02). Among women, these associations were less clear (≥175 vs 160–164 cm, pooled OR for glioma = 1.06, 95% CI: 0.70–1.62; P-trend = 0.22; pooled OR for glioblastoma = 1.36, 95% CI: 0.77–2.39; P-trend = 0.04). In general, we did not observe evidence of effect modification by glioma-related genotypes on the association between height and glioma risk.Conclusion An association of taller adult stature with glioma, particularly for men and stronger for glioblastoma, should be investigated further to clarify the role of environmental and genetic determinants of height in the etiology of this disease. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
26. New Models for Large Prospective Studies: Is There a Better Way?
- Author
-
Manolio, Teri A., Weis, Brenda K., Cowie, Catherine C., Hoover, Robert N., Hudson, Kathy, Kramer, Barnett S., Berg, Chris, Collins, Rory, Ewart, Wendy, Gaziano, J. Michael, Hirschfeld, Steven, Marcus, Pamela M., Masys, Daniel, McCarty, Catherine A., McLaughlin, John, Patel, Alpa V., Peakman, Tim, Pedersen, Nancy L., Schaefer, Catherine, and Scott, Joan A.
- Published
- 2012
27. Fruit and Vegetable Intake and the Risk of Hypertension in Middle-Aged and Older Women.
- Author
-
Wang, Lu, Manson, JoAnn E., Gaziano, J. Michael, Buring, Julie E., and Sesso, Howard D.
- Subjects
HYPERTENSION ,FRUIT ,VEGETABLES ,HYPERTENSION in women ,HYPERTENSION in old age ,THERAPEUTICS - Abstract
BackgroundDespite the promising findings from short-term intervention trials, the long-term effect of habitual fruit and vegetable intake on blood pressure (BP) remains uncertain. We therefore assessed the prospective association between baseline intake of fruits and vegetables and the risk of hypertension in a large cohort of middle-aged and older women.MethodsWe conducted analyses among 28,082 US female health professionals aged ≥39 years, free of cardiovascular disease, cancer, and hypertension at baseline. Baseline intake of fruits and vegetables was assessed using semiquantitative food frequency questionnaires (FFQs). Incident hypertension was identified from annual follow-up questionnaires.ResultsDuring 12.9 years of follow-up, 13,633 women developed incident hypertension. After basic adjustment including age, race, and total energy intake, the hazard ratio (HR) and 95% confidence interval (CI) of hypertension was 0.97 (0.89-1.05), 0.93 (0.85-1.01), 0.89 (0.82-0.97), and 0.86 (0.78-0.94) comparing women who consumed 2- <4, 4- <6, 6- <8, and ≥8 servings/day of total fruits and vegetables with those consuming <2 servings/day. These associations did not change after additionally adjusting for lifestyle factors but were attenuated after further adjustment for other dietary factors. When fruits and vegetables were analyzed separately, higher intake of all fruits but not all vegetables remained significantly associated with reduced risk of hypertension after adjustment for lifestyle and dietary factors. Adding body mass index (BMI) to the models eliminated all associations.ConclusionsHigher intake of fruits and vegetables, as part of a healthy dietary pattern, may only contribute a modest beneficial effect to hypertension prevention, possibly through improvement in body weight regulation.American Journal of Hypertension (2012). doi:10.1038/ajh.2011.186 [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
28. Prediagnostic Plasma IgE Levels and Risk of Adult Glioma in Four Prospective Cohort Studies.
- Author
-
Calboli, Federico C. F., Cox, David G., Buring, Julie E., Gaziano, J. Michael, Ma, Jing, Stampfer, Meir, Willett, Walter C., Tworoger, Shelley S., Hunter, David J., Camargo, Carlos A., and Michaud, Dominique S.
- Subjects
GLIOMAS ,IMMUNOGLOBULINS ,ALLERGIES ,FOOD allergy ,NERVOUS system tumors ,DISEASE risk factors - Abstract
Background Increased levels of serum immunoglobulin E (IgE) because of allergies have been inversely associated with risk of glioma in observational studies. Despite consistency across studies examining history of allergies and glioma, questions remain as to whether those are causal associations. An inverse association between serum IgE and risk of glioma was reported in a large case–control study, but reverse causality and treatment effects remain potential explanations for those findings. Methods We combined data from four prospective cohort studies and used a nested case–control design to examine the association between allergy and glioma. We included glioma case subjects who were confirmed from medical or pathology records or from death certificates, and with prediagnostic blood available. We matched three control subjects per case subject, and the final numbers for analyses were 169 case subjects and 520 control subjects. Total IgE, food allergen–specific IgE, and respiratory allergen–specific IgE levels were measured using a highly sensitive fluorescent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression analysis. Stratified analyses were conducted by age and birth cohorts. Results Borderline elevated total IgE levels (25–100 kU/L) showed a statistically significant inverse association with glioma (OR = 0.63, 95% CI = 0.42 to 0.93), but no association was noted between elevated IgE (>100 kU/L) and glioma (OR = 0.98, 95% CI = 0.61 to 1.56) compared with clinically normal IgE levels (<25 kU/L). The association between glioma and total IgE was consistent for both men and women. Non-statistically significant inverse associations were noted for elevated IgE levels among individuals born before year 1930 (OR = 0.67, 95% CI = 0.34 to 1.34) and when restricting analyses to highly fatal (deceased within 2 years of diagnosis) glioma case subjects (OR = 0.64, 95% CI = 0.34 to 1.19) compared with individuals with clinically normal IgE levels. No associations were observed for either food allergen–specific or respiratory allergen–specific IgE levels. Conclusions Overall, our prospective findings are consistent with recent retrospective studies and support an association between total IgE levels and glioma. However, this association requires further elucidation. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
29. Statins and Prostate Cancer Diagnosis and Grade in a Veterans Population.
- Author
-
Farwell, Wildon R., D'Avolio, Leonard W., Scranton, Richard E., Lawler, Elizabeth V., and Gaziano, J. Michael
- Subjects
PROSTATE cancer ,CANCER prevention ,STATINS (Cardiovascular agents) ,CANCER risk factors ,CLINICAL trials - Abstract
Background Although prostate cancer is commonly diagnosed, few risk factors for high-grade prostate cancer are known and few prevention strategies exist. Statins have been proposed as a possible treatment to prevent prostate cancer. Methods Using electronic and administrative files from the Veterans Affairs New England Healthcare System, we identified 55 875 men taking either a statin or antihypertensive medication. We used age- and multivariable-adjusted Cox proportional hazard models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for prostate cancer incidence among patients taking statins (n = 41 078) compared with patients taking antihypertensive medications (n = 14 797). We performed similar analyses for all lipid parameters including total cholesterol examining each lipid parameter as a continuous variable and by quartiles. All statistical tests were two-sided. Results Compared with men taking an antihypertensive medication, statin users were 31% less likely (HR = 0.69, 95% CI = 0.52 to 0.90) to be diagnosed with prostate cancer. Furthermore, statin users were 14% less likely (HR = 0.86, 95% CI = 0.62 to 1.20) to be diagnosed with low-grade prostate cancer and 60% less likely (HR = 0.40, 95% CI = 0.24 to 0.65) to be diagnosed with high-grade prostate cancer compared with antihypertensive medication users. Increased levels of total cholesterol were also associated with both total (HR = 1.02, 95% CI = 1.00 to 1.05) and high-grade (HR = 1.06, 95% CI = 1.02 to 1.10) prostate cancer incidence but not with low-grade prostate cancer incidence (HR = 1.01, 95% CI = 0.98 to 1.04). Conclusions Statin use is associated with statistically significantly reduced risk for total and high-grade prostate cancer, and increased levels of serum cholesterol are associated with higher risk for total and high-grade prostate cancer. These findings indicate that clinical trials of statins for prostate cancer prevention are warranted. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
30. Circulating Inflammatory and Endothelial Markers and Risk of Hypertension in White and Black Postmenopausal Women.
- Author
-
Wang, Lu, Manson, JoAnn E., Gaziano, J. Michael, Liu, Simin, Cochrane, Barbara, Cook, Nancy R., Ridker, Paul M., Rifai, Nader, and Sesso, Howard D.
- Published
- 2011
- Full Text
- View/download PDF
31. Hemoglobin A1c, Body Mass Index, and the Risk of Hypertension in Women.
- Author
-
Britton, Kathryn A., Pradhan, Aruna D., Gaziano, J. Michael, Manson, JoAnn E., Ridker, Paul M., Buring, Julie E., and Sesso, Howard D.
- Subjects
HEMOGLOBINS ,BODY mass index ,HYPERTENSION in women ,DISEASES in women ,DISEASE risk factors ,EPIDEMIOLOGY - Abstract
BackgroundAlthough basic research has implicated abnormal glucose metabolism in the pathogenesis of hypertension (HTN), epidemiologic studies are limited.MethodsWe assessed whether baseline hemoglobin A
1c (HbA1c ) was prospectively associated with HTN in the Women's Health Study (WHS). We analyzed 19,858 women initially free of HTN, diabetes, and cardiovascular disease (CVD) with baseline blood samples. We considered quintiles and clinical cutpoints of HbA1c for the risk of HTN, defined as either a new physician diagnosis, the initiation of antihypertensive treatment, or systolic blood pressure (SBP) ≥140 or diastolic blood pressure (DBP) ≥90 mm Hg.ResultsDuring a median follow-up of 11.6 years, 9,408 (47.5%) women developed HTN. In models adjusted for traditional cardiovascular risk factors, the hazard ratios (HRs) from the lowest (<4.8%, referent) to the highest (≥5.2%) quintile of HbA1c were 1.0 (referent), 0.99, 1.06, 1.08, and 1.21 (P, linear trend <0.0001). However, additional adjustment for body mass index (BMI) eliminated the relation (extreme quintile comparison HR 1.04; P, linear trend 0.10). For clinical cutpoints, a similar pattern emerged although a positive association between HbA1c and HTN remained in the highest category.ConclusionsHbA1c in women without diabetes was associated with an increased risk of HTN in models controlling for the majority of traditional HTN and coronary risk factors, but this relation was no longer significant after adjustment for BMI. These findings underscore the need for additional studies to delineate the important inter-relationships between glycemia and adiposity with the risk of HTN in other study populations.American Journal of Hypertension (2011). doi:10.1038/ajh.2010.233 [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
32. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians†.
- Author
-
Schumacher, Fredrick R., Cheng, Iona, Freedman, Matthew L., Mucci, Lorelei, Allen, Naomi E., Pollak, Michael N., Hayes, Richard B., Stram, Daniel O., Canzian, Federico, Henderson, Brian E., Hunter, David J., Virtamo, Jarmo, Manjer, Jonas, Gaziano, J. Michael, Kolonel, Laurence N., Tjønneland, Anne, Albanes, Demetrius, Calle, Eugenia E., Giovannucci, Edward, and Crawford, E. David
- Published
- 2010
- Full Text
- View/download PDF
33. Chronic Disease in Men With Newly Diagnosed Cancer: A Nested Case-Control Study.
- Author
-
Driver, Jane A., Yung, Rachel, Gaziano, J. Michael, and Kurth, Tobias
- Subjects
MEN'S health ,AGE factors in disease ,CANCER patients ,CHRONIC diseases ,CORONARY disease ,HEART blood-vessels - Abstract
The authors performed a matched case-control study (1982–2007) nested in a prospective cohort of 22,071 US men to determine the prevalence of chronic diseases of aging in those with newly diagnosed cancer. They matched one control by age to each of 5,622 men who developed cancer over the 25 years of follow-up, as of the date of cancer diagnosis. A modified Charlson score was calculated that reflected comorbidities prior to the matching date, and the authors used conditional logistic regression to determine the odds ratios of various diseases. No substantial differences were found between the scores of cases and controls overall, by cancer subtype, or by age at diagnosis. Overall, men who developed cancer were less likely to have had hypercholesterolemia (odds ratio (OR) = 0.79, 95% confidence interval (CI): 0.72, 0.87) or coronary artery disease (OR = 0.85, 95% CI: 0.77, 0.96). Compared with controls, men with cancers for which there is routine screening had fewer diseases, whereas those with smoking-related cancers had more. Prostate cancer was inversely associated with both coronary artery disease (OR = 0.72, 95% CI: 0.62, 0.84) and diabetes (OR = 0.72, 95% CI: 0.58, 0.89). Overall, men who developed cancer had no more comorbidity or frequent history of chronic disease than their age-matched controls. [ABSTRACT FROM PUBLISHER]
- Published
- 2010
- Full Text
- View/download PDF
34. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
- Author
-
Lawler, Elizabeth V., Gagnon, David R., Fink, Jeffrey, Seliger, Stephen, Fonda, Jennifer, Do, Thy P., Gaziano, J. Michael, and Bradbury, Brian D.
- Subjects
ANEMIA treatment ,ERYTHROPOIESIS ,KIDNEY disease treatments ,HEMODIALYSIS patients - Abstract
Background. Erythropoiesis-stimulating agents (ESAs) are frequently used to treat anaemia of chronic kidney disease (CKD) in the dialysis setting; however, few data are available regarding factors influencing initiation of ESAs and other therapies in non-dialysis patients. [ABSTRACT FROM PUBLISHER]
- Published
- 2010
- Full Text
- View/download PDF
35. Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3).
- Author
-
Ahn, Jiyoung, Schumacher, Fredrick R., Berndt, Sonja I., Pfeiffer, Ruth, Albanes, Demetrius, Andriole, Gerald L., Ardanaz, Eva, Boeing, Heiner, Bueno-de-Mesquita, Bas, Chanock, Stephen J., Clavel-Chapelon, Françoise, Diver, W. Ryan, Feigelson, Heather Spencer, Gaziano, J. Michael, Giovannucci, Edward, Haiman, Christopher A., Henderson, Brian E., Hoover, Robert N., Kolonel, Laurence N., and Kraft, Peter
- Published
- 2009
- Full Text
- View/download PDF
36. US Department of Veterans Affairs Medical Care System as a Resource to Epidemiologists.
- Author
-
Boyko, Edward J., Koepsell, Thomas D., Gaziano, J. Michael, Horner, Ronnie D., and Feussner, John R.
- Subjects
PUBLIC health surveillance ,MEDICAL care of veterans ,VETERANS' health ,EPIDEMIOLOGY methodology - Abstract
Epidemiologists have utilized several health care systems with large numbers of enrollees and centralized databases to achieve their research aims. Although containing many of the features that have made certain health care systems valuable to the conduct of epidemiologic research, the US Department of Veterans Affairs (VA) medical care system has not been well utilized by epidemiologists. This article will describe existing and planned features of this health care system that should be of interest to epidemiologists, including centralized databases that capture hospital discharge and outpatient clinic diagnostic data, a planned enrollment file that would contain all persons eligible for VA medical care, and the size and national dispersion of VA medical care facilities. Also, VA leadership has demonstrated an interest in the promotion of epidemiologic research by initiating several new programs, including the creation of three Epidemiologic Research and Information Centers (ERICs) to foster VA epidemiologic research, and announcing a program to support investigator-initiated epidemiologic research projects with VA funding. Epidemiologists with interests in medical problems that afflict veterans should consider partnerships with VA investigators to achieve their research aims. Am J Epidemiol 2000; 151: 307–14. [ABSTRACT FROM PUBLISHER]
- Published
- 2009
37. Vitamins C and E and Beta Carotene Supplementation and Cancer Risk: A Randomized Controlled Trial.
- Author
-
Lin, Jennifer, Cook, Nancy R., Albert, Christine, Zaharris, Elaine, Gaziano, J. Michael, Van Denburgh, Martin, Buring, Julie E., and Manson, JoAnn E.
- Subjects
RANDOMIZED controlled trials ,VITAMIN C ,VITAMIN E ,ANTIOXIDANTS ,CANCER risk factors ,VITAMINS - Abstract
Background Observational studies suggested that a diet high in fruits and vegetables, both of which are rich with antioxidants, may prevent cancer development. However, findings from randomized trials of the association between antioxidant use and cancer risk have been mostly negative. Methods From 8171 women who were randomly assigned in the Women's Antioxidant Cardiovascular Study, a double-blind, placebo-controlled 2 x 2 x 2 factorial trial of vitamin C (500 mg of ascorbic acid daily), natural-source vitamin E (600 IU of α-tocopherol every other day), and beta carotene (50 mg every other day), 7627 women who were free of cancer before random assignment were selected for this study. Diagnoses and deaths from cancer at a specific site were confirmed by use of hospital reports and the National Death Index. Cox proportional hazards regression models were used to assess hazard ratios (represented as relative risks [RRs]) of common cancers associated with use of antioxidants, either individually or in combination. Subgroup analyses were conducted to determine if duration of use modified the association of supplement use with cancer risk. All statistical tests were two-sided. Results During an average 9.4 years of treatment, 624 women developed incident invasive cancer and 176 women died from cancer. There were no statistically significant effects of use of any antioxidant on total cancer incidence. Compared with the placebo group, the RRs were 1.11 (95% confidence interval [Cl] = 0.95 to 1.30) in the vitamin C group, 0.93 (95% Cl = 0.79 to 1.09) in the vitamin E group, and 1.00 (95% Cl = 0.85 to 1.17) in the beta carotene group. Similarly, no effects of these antioxidants were observed on cancer mortality. Compared with the placebo group, the RRs were 1.28(95% Cl = 0.95 to 1.73) in the vitamin C group, 0.87(95% Cl = 0.65 to 1.17) in the vitamin F group, and 0.84(95% Cl = 0.62 to 1.13) in the beta carotene group. Duration and combined use of the three antioxidants also had no effect on cancer incidence and cancer death. Conclusions Supplementation with vitamin C, vitamin E, or beta carotene offers no overall benefits in the primary prevention of total cancer incidence or cancer mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
38. Smoking and the Risk of Incident Hypertension in Middle-aged and Older Men.
- Author
-
Halperin, Ruben O., Gaziano, J. Michael, and Sesso, Howard D.
- Subjects
HYPERTENSION in old age ,RISK assessment ,HEALTH of cigarette smokers ,CARDIOVASCULAR diseases ,EPIDEMIOLOGICAL research - Abstract
BACKGROUND Cigarette smoking is a known risk factor for cardiovascular disease (CVD), but its relationship to the development of hypertension is unclear. Previous epidemiological studies have shown inconsistent results, having demonstrated inverse and positive associations between cigarette smoking and the development of hypertension. METHODS We analyzed 13,529 male participants from the Physicians' Health Study free of baseline hypertension and CVD who provided information about smoking status. Smoking status was categorized as never, past, or current <20 cigarettes/day, or current ≥20 cigarettes/day. Incident hypertension was defined as either the initiation of antihypertensive treatment, self-reported systolic blood pressure (BP) ≥140 mm Hg, or diastolic BP ≥90 mm Hg. RESULTS Over a median follow-up of 14.5 years, 4,904 men developed hypertension. We modeled the risk of developing hypertension by baseline smoking status adjusting for known risk factors for hypertension or CVD. In a fully adjusted Cox proportional hazards model, we found that compared with never smokers, past smokers and current smokers had corresponding relative risks (RRs) of 1.08 and 1.15 of developing hypertension. The risk for smokers did not appear to differ based on number of cigarettes smoked daily. Further, the RR of hypertension was higher for men with normal vs. prehypertensive levels of systolic (SBP) or diastolic BP (DBP). CONCLUSIONS This prospective cohort data suggests that cigarette smoking may be a modest but important risk factor for the development of hypertension. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
39. The Association Between Statins and Cancer Incidence in a Veterans Population.
- Author
-
Farwell, Wildon R., Scranton, Richard E., Lawler, Elizabeth V., Lew, Robert A., Brophy, Mary T., Fiore, Louis D., and Gaziano, J. Michael
- Subjects
STATINS (Cardiovascular agents) ,CANCER ,CARDIOVASCULAR diseases ,DISEASE incidence ,DISEASES in veterans - Abstract
Background: Meta-analyses of trials of 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors or statins for cardiovascular disease prevention have failed to show any statistically significant benefit of statins for cancer prevention. However, these trials included relatively young participants, who develop few cancers, and their follow-up periods may have been too short to detect an association between statin use and cancer incidence. We investigated this association in a population of veterans. Methods: We identified patients using antihypertensive medications but no cholesterol-lowering medications (n = 25594) and patients using statins (n = 37248) who were enrolled in the Veterans Affairs New England Healthcare System between January 1, 1997, and December 31, 2005. Age- and multivariable-adjusted Cox proportional hazards models were used to calculate the hazard ratio (HR) and its 95% confidence interval (Cl) for cancer incidence, excluding nonmelanoma skin cancer, among patients taking statins compared with patients taking antihypertensive medications and among patients grouped by statin dose (as equivalent simvastatin dose). All statistical tests were two-sided. Results: The absolute incidence of total cancers was 9.4% among statin users and 13.2% among nonusers (difference = 3.8%, 95% Cl = 3.3% to 4.3%, P
difference < .001). Statin users had a statistically significant lower risk for total cancer than nonusers after adjustment for age (HR = 0.76, 95% Cl = 0.73 to 0.80) and multiple potential confounders (HR = 0.74, 95% Cl = 0.70 to 0.78). After multivariable adjustment, a statistically significantly decreased risk of all cancers was also associated with increasing statin use (Ptrend < .001). Conclusions: Patients using statins may be at lower risk for developing cancer. Additional observational studies and randomized trials of statins for cancer prevention are warranted. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
40. A Prospective Study of Body Mass Index and the Risk of Developing Hypertension in Men
- Author
-
Gelber, Rebecca P., Gaziano, J. Michael, Manson, JoAnn E., Buring, Julie E., and Sesso, Howard D.
- Subjects
HYPERTENSION ,BODY mass index ,DISEASES in men ,DISEASE risk factors - Abstract
Background: Although obesity is known to increase the risk of hypertension, few studies have prospectively evaluated body mass index (BMI) across the range of normal weight and overweight as a primary risk factor. Methods: In this prospective cohort, we evaluated the association between BMI and risk of incident hypertension. We studied 13,563 initially healthy, nonhypertensive men who participated in the Physicians’ Health Study. We calculated BMI from self-reported weight and height and defined hypertension as self-reported systolic blood pressure (BP) ≥140 mm Hg, diastolic BP ≥90 mm Hg, or new antihypertensive medication use. Results: After a median 14.5 years, 4920 participants developed hypertension. Higher baseline BMI, even within the “normal” range, was consistently associated with increased risk of hypertension. Compared to participants in the lowest BMI quintile (<22.4 kg/m
2 ), the relative risks (95% confidence interval) of developing hypertension for men with a BMI of 22.4 to 23.6, 23.7 to 24.7, 24.8 to 26.4, and >26.4 kg/m2 were 1.20 (1.09–1.32), 1.31 (1.19–1.44), 1.56 (1.42–1.72), and 1.85 (1.69–2.03), respectively (P for trend, <.0001). Further adjustment for diabetes, high cholesterol, and baseline BP did not substantially alter these results. We found similar associations using other BMI categories and after excluding men with smoking history, those who developed hypertension in the first 2 years, and those with diabetes, obesity, or high cholesterol at baseline. Conclusions: In this large cohort, we found a strong gradient between higher BMI and increased risk of hypertension, even among men within the “normal” and mildly “overweight” BMI range. Approaches to reduce the risk of developing hypertension may include prevention of overweight and obesity. [Copyright &y& Elsevier]- Published
- 2007
- Full Text
- View/download PDF
41. Results of Multivariable Logistic Regression, Propensity Matching, Propensity Adjustment, and Propensity-based Weighting under Conditions of Nonuniform Effect.
- Author
-
Kurth, Tobias, Walker, Alexander M., Glynn, Robert J., Chan, K. Arnold, Gaziano, J. Michael, Berger, Klaus, and Robins, James M.
- Subjects
REGRESSION analysis ,PLASMINOGEN activators ,CEREBROVASCULAR disease patients ,MORTALITY ,EPIDEMIOLOGICAL research ,RESEARCH methodology - Abstract
Observational studies often provide the only available information about treatment effects. Control of confounding, however, remains challenging. The authors compared five methods for evaluating the effect of tissue plasminogen activator on death among 6,269 ischemic stroke patients registered in a German stroke registry: multivariable logistic regression, propensity score–matched analysis, regression adjustment with the propensity score, and two propensity score–based weighted methods—one estimating the treatment effect in the entire study population (inverse-probability-of-treatment weights), another in the treated population (standardized-mortality-ratio weights). Between 2000 and 2001, 212 patients received tissue plasminogen activator. The crude odds ratio between tissue plasminogen activator and death was 3.35 (95% confidence interval: 2.28, 4.91). The adjusted odds ratio depended strongly on the adjustment method, ranging from 1.11 (95% confidence interval: 0.67, 1.84) for the standardized-mortality-ratio weighted to 10.77 (95% confidence interval: 2.47, 47.04) for the inverse-probability-of-treatment-weighted analysis. For treated patients with a low propensity score, risks of dying were high. Exclusion of patients with a propensity score of <5% yielded comparable odds ratios of approximately 1 for all methods. High levels of nonuniform treatment effect render summary estimates very sensitive to the weighting system explicit or implicit in an adjustment technique. Researchers need to be clear about the population for which an overall treatment estimate is most suitable. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
42. Effect of Age on Blood Pressure Parameters and Risk of Cardiovascular Death in Men
- Author
-
Bowman, Thomas S., Sesso, Howard D., and Gaziano, J. Michael
- Subjects
BLOOD pressure ,CARDIOVASCULAR diseases ,DISEASE risk factors ,DEATH ,HYPERTENSION - Abstract
Background: Elevated blood pressure (BP) is a risk factor for cardiovascular disease (CVD), but it remains unclear which component—alone or in combination—is the best predictor. We sought to determine which BP parameters are important predictors of CVD death across a wide age range. Methods: We used a prospective cohort study design with 53,163 men followed for cause-specific death during a median of 5.7 years in the Physicians’ Health Study enrollment cohort. Baseline age, systolic BP and diastolic BP were collected. We calculated relative risks (RRs) and their 95% confidence intervals using Cox proportional hazard models adjusting for major risk factors for CVD, and then stratified by age (39 to 49, 50 to 59, 60 to 69, and 70 to 84 years). Results: There were 459 CVD deaths during follow-up. For each 10 mm Hg increase in systolic BP, the multivariable RRs by ascending age group were 1.46, 1.43, 1.24, and 1.13. The multivariable RRs for each 10 mm Hg increase in diastolic BP were 1.25, 1.20, 1.28, and 1.07. Compared with systolic BP, pulse pressure and mean arterial pressure were not consistent predictors across age ranges, and combining systolic BP with another parameter did not improve the model compared with using systolic BP alone in any age group (all P > .05). Conclusions: In this large cohort of healthy men with no history of hypertension, systolic BP was the most consistent and significant predictor of CVD death across all ages. Diastolic BP was not as strongly associated with risk. Our results support the continuing emphasis on using systolic BP in predicting cardiovascular risk. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
43. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
- Author
-
Lippman, Scott M., Goodman, PhylIis J., Klein, Eric A., Parnes, Howard L., Thompson Jr., Ian M., Kristal, Alan R., SantelIa, Regina M., Probstfield, Jeffrey L., Moinpour, Carol M., Albanes, Demetrius, Taylor, Philip R., Minasian, Lori M., Hoque, Ash Raful, Thomas, Sarah Moody, Crowlev, John J., Gaziano, J. Michael, Stanford, Janet L., Cook, Elise D., Fleshner, Neil E., and Lieber, Michael M.
- Subjects
PROSTATE cancer ,AFRICAN Americans ,SELENIUM ,VITAMIN E ,CANCER prevention ,CANCER patients ,MEDICAL care - Abstract
Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32 400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 μg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac α-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non-African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
44. Comparison of Self-Report, Hospital Discharge Codes, and Adjudication of Cardiovascular Events in the Women’s Health Initiative.
- Author
-
Heckbert, Susan R., Kooperberg, Charles, Safford, Monika M., Psaty, Bruce M., Hsia, Judith, McTiernan, Anne, Gaziano, J. Michael, Frishman, William H., and Curb, J. David
- Subjects
CARDIOVASCULAR diseases ,CLINICAL trials ,HEART failure ,MYOCARDIAL infarction ,PERIPHERAL vascular disease diagnosis ,PULMONARY embolism - Abstract
Limited information is available from large clinical investigations about the agreement among sources of diagnoses for endpoints. The authors used data from the Women’s Health Initiative clinical trials and observational study from January 1994 to November 2000 to evaluate the agreement among self-report, hospital discharge codes, and two different levels of physician review of medical records for cardiovascular endpoints. For myocardial infarction, stroke, pulmonary embolism, and venous thrombosis, the agreement of hospital discharge codes or self-report with review by study physicians at clinical centers was substantial (kappa = 0.64–0.84). For coronary revascularization, agreement among these sources of information was substantial to almost perfect (kappa = 0.79–0.92), but for angina, congestive heart failure, and peripheral vascular disease, concordance was only fair to moderate (kappa = 0.37–0.56), indicating that these endpoints remain difficult to classify reliably. Agreement between physician adjudicators at clinical centers and central physician adjudicators was substantial to almost perfect (kappa = 0.67–0.94). The findings also suggest that, for the endpoint of myocardial infarction, physician review of events with hospital discharge codes for angina and congestive heart failure is an important source of validated events, and for stroke, review of all events with cerebrovascular codes is important. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
45. A Prospective Study of Plasma Selenium Levels and Prostate Cancer Risk.
- Author
-
Haojie Li, Stampfer, Meir J., Giovannucci, Edward L., Morris, J. Steven, Willett, Walter C., Gaziano, J. Michael, and Jing Ma
- Subjects
EPIDEMIOLOGY ,TUMORS ,SELENIUM ,PROSTATE cancer ,DIAGNOSIS - Abstract
Epidemiologic studies suggest that low selenium levels are associated with an increased incidence of prostate cancer, although results are conflicting. We examined the association between pre-diagnostic plasma selenium levels and risk of prostate cancer in men enrolled in the Physicians' Health Study. Pre-diagnostic plasma selenium levels were inversely associated with risk of advanced prostate cancer (5
th versus 1st quintile OR = 0.52, 95% CI = 0.28 to 0.98; Ptrend = .05), even among men diagnosed after 1990 (5th versus 1st quintile OR = 0.39, 95% CI = 0.16 to 0.97). The inverse association with prostate cancer risk was observed only for case subjects with elevated baseline PSA levels (PSA >4 ng/mL, 5th versus 1st quintile OR = 0.49, 95% CI = 0.28 to 0.86; Ptrend = .002). These inverse associations were observed in both pre- and post-PSA eras. The inverse association between baseline plasma selenium levels and risk of advanced prostate cancer, even among men diagnosed during the post-PSA era, suggests that higher levels of selenium may slow prostate cancer tumor progression. Ongoing randomized trials of selenium supplements may help to further evaluate this issue. [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
46. A prospective study of plasma C-peptide and colorectal cancer risk in men.
- Author
-
Ma, Jing, Giovannucci, Edward, Pollak, Michael, Leavitt, Azita, Tao, Yuzhen, Gaziano, J Michael, and Stampfer, Meir J
- Abstract
Background: Colorectal cancer and type 2 diabetes share many risk factors, and hyperinsulinemia appears to be associated with an increased risk of colorectal cancer. We used the concentration of plasma C-peptide (an indicator of insulin production) to determine whether insulin and insulin resistance are associated with the risk of developing colorectal cancer.Methods: We conducted a nested case-control study in the Physicians' Health Study. Plasma samples were collected from 14 916 cancer-free men from August 1982 through December 1984. Plasma C-peptide concentration, measured with an enzyme-linked immunosorbent assay, was available for 176 case patients who developed incident colorectal cancer through December 31, 1995, and 294 age- and smoking status-matched control subjects. Information on four other insulin resistance-related factors at baseline was obtained. We used conditional logistic regression models to investigate associations. All statistical tests were two-sided.Results: Plasma C-peptide concentration was positively associated with age, body mass index (BMI), and number of insulin resistance-related factors, and it was inversely associated with fasting time before the blood draw, alcohol consumption, and vigorous exercise. An increased concentration of plasma C-peptide was statistically significantly associated with an increased risk of colorectal cancer (relative risk [RR] for the highest versus lowest quintile of plasma C-peptide = 2.7, 95% confidence interval [CI] = 1.2 to 6.2; P(trend) =.047), after adjusting for age, smoking status, fasting, BMI, alcohol consumption, vigorous exercise, and aspirin assignment in the Physicians' Health Study. The association became even stronger when the analysis was further adjusted for factors related to insulin resistance other than insulin levels (RR for the highest versus lowest quintile = 3.4, 95% CI = 1.4 to 8.3; P(trend) =.02) or when data from case patients who were diagnosed during the first 5 years of follow-up were excluded (RR for the highest versus the lowest quintile = 3.4, 95% CI = 1.3 to 8.8; P(trend) =.03). Adjusting for plasma levels of insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) did not materially change the results. There was no apparent modification of risk by BMI, insulin resistance-related factors, or vigorous exercise.Conclusion: Elevated insulin production, as reflected by elevated concentrations of plasma C-peptide, may predict the risk of developing colorectal cancer, independently of BMI, factors related to insulin resistance, or levels of IGF-I and IGFBP-3. [ABSTRACT FROM AUTHOR]- Published
- 2004
47. A Prospective Study of Plasma C-Peptide and Colorectal Cancer Risk in Men.
- Author
-
Jing Ma, Giovannucci, Edward, Pollak, Michael, Leavitt, Azita, Tao, Yuzhen, Gaziano, J. Michael, and Stampfer, Meir J.
- Subjects
C-peptide ,PEPTIDES ,INSULIN ,COLON cancer ,DISEASES in men ,CANCER in men - Abstract
Background: Colorectal cancer and type 2 diabetes share many risk factors, and hyperinsulinemia appears to be associated with an increased risk of colorectal cancer. We used the concentration of plasma C-peptide (an indicator of insulin production) to determine whether insulin and insulin resistance are associated with the risk of developing colorectal cancer. Methods: We conducted a nested case-control study in the Physicians' Health Study. Plasma samples were collected from 14 916 cancer-free men from August 1982 through December 1984. Plasma C-peptide concentration, measured with an enzyme-linked immunosorbent assay, was available for 176 case patients who developed incident colorectal cancer through December 31, 1995, and 294 age- and smoking status-matched control subjects. Information on four other insulin resistance-related factors at baseline was obtained. We used conditional logistic regression models to investigate associations. All statistical tests were two-sided. Results: Plasma C-peptide concentration was positively associated with age, body mass index (BMI), and number of insulin resistance-related factors, and it was inversely associated with fasting time before the blood draw, alcohol consumption, and vigorous exercise. An increased concentration of plasma C-peptide was statistically significantly associated with an increased risk of colorectal cancer (relative risk [RR] for the highest versus lowest quintile of plasma C-peptide = 2.7, 95% confidence interval [CI] = 1.2 to 6.2; P
trend = .047), after adjusting for age, smoking status, fasting, BMI, alcohol consumption, vigorous exercise, and aspirin assignment in the Physicians' Health Study. The association became even stronger when the analysis was further adjusted for factors related to insulin resistance other than insulin levels (RR for the highest versus lowest quintile = 3.4, 95% CI = 1.4 to 8.3; Ptrend = .02) or when data from case patients who were diagnosed during the first 5 years of follow-up were excluded (RR for the highest versus the lowest quintile = 3.4, 95% CI = 1.3 to 8.8; Ptrend = .03). Adjusting for plasma levels of insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) did not materially change the results. There was no apparent modification of risk by BMI, insulin resistancerelated factors, or vigorous exercise. Conclusion: Elevated insulin production, as reflected by elevated concentrations of plasma C-peptide, may predict the risk of developing colorectal cancer, independently of BMI, factors related to insulin resistance, or levels of IGF-I and IGFBP-3. [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
48. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.
- Author
-
Chan, June M., Stampfer, Meir J., Jing Ma, Gann, Peter, Gaziano, J. Michael, Pollack, Michael, Giovannucci, Edward, Ma, Jing, and Pollak, Michael
- Subjects
PROSTATE cancer ,INSULIN-like growth factor-binding proteins ,LOGISTIC regression analysis - Abstract
Background: Plasma levels of insulin-like growth factor-I (IGF-I) have been associated with the risk of prostate cancer. However, the association of IGF-I with specific tumor stage and grade at diagnosis, which correlate with risk of recurrence and mortality, has not been studied rigorously. To determine whether plasma levels of IGF-I and its main circulating binding protein, IGF binding protein-3 (IGFBP-3), predict more aggressive forms of prostate cancer, we investigated the association between plasma levels of each and specific stages and grades of prostate cancer.Methods: We examined 530 case patients and 534 control subjects in a nested case-control study in the prospective Physicians' Health Study. Patients with prostate cancer diagnosed from 1982 through 1995 were matched to control subjects by age and smoking status. IGF-I and IGFBP-3 were measured in prospectively collected plasma samples. Conditional logistic regression models were used to estimate the relative risks (RRs) for prostate cancer associated with IGF-I and IGFBP-3, stratified on grade (Gleason score > or = 7 versus <7) and stage (early = stage A or B prostate cancer versus advanced = stage C or D prostate cancer). All statistical tests were two-sided.Results: Plasma levels of IGF-I and IGFBP-3 were predictors of advanced-stage prostate cancer (RR = 5.1, 95% confidence interval [CI] = 2.0 to 13.2 for highest versus lowest quartiles of IGF-I; RR = 0.2, 95% CI = 0.1 to 0.6 for highest versus lowest quartiles of IGFBP-3) but not of early-stage prostate cancer. Neither was differentially associated with Gleason score. Men with high IGF-I levels and low IGFBP-3 levels had an RR for advanced-stage prostate cancer of 9.5 (95% CI = 1.9 to 48.4) compared with men with low levels of both. Combining IGF-I and IGFPB-3 measurements with a standard prostate-specific antigen (PSA) measurement for prostate cancer screening increased the specificity (from 91% to 93%) but decreased sensitivity (from 40% to 36%) compared with measurement of PSA alone.Conclusions: Circulating levels of IGF-I and IGFBP-3 may predict the risk of developing advanced-stage prostate cancer, but their utility for screening patients with incident prostate cancer may be limited. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
49. Stroke Risk Predicts Verbal Fluency Decline in Healthy Older Men: Evidence From the Normative...
- Author
-
Brady, Christopher B., Spiro III, Avron, Milberg, William, McGlinchey-Berroth, Regina, and Gaziano, J. Michael
- Subjects
OLDER men ,CEREBROVASCULAR disease risk factors ,VERBAL ability ,DISEASES in older people - Abstract
Discusses results of a study examining the risk for stroke among healthy older men with declining verbal fluency. Age demographics; Calculation of stroke risk; Hypertension; Diabetes mellitus; Atrial fibrillation; Left ventricular hypertrophy.
- Published
- 2001
- Full Text
- View/download PDF
50. Milk Intake, Circulating Levels of Insulin-Like Growth Factor-I, and Risk of Colorectal Cancer....
- Author
-
Jing Ma, Giovannucci, Edward, Pollak, Michael, Chan, June M., Gaziano, J. Michael, Willett, Walter, and Stampfer, Meir J.
- Subjects
COLON cancer ,NUTRITIONALLY induced diseases ,MILK - Abstract
Examines the effect of milk and dietary calcium on colorectal cancer. Increase the serum levels of insulin-like growth factor-I (IGF-I); Usage of conditional logistic regression in relative risks of cancer; Interaction between low-fat milk intake and IGF-I.
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.